AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 207 filers reported holding AMICUS THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $877,000 | -74.1% | 88,705 | -39.6% | 0.01% | -73.9% |
| Q4 2020 | $3,390,000 | +46.1% | 146,806 | -10.7% | 0.02% | +43.8% |
| Q3 2020 | $2,321,000 | -24.5% | 164,406 | -19.3% | 0.02% | -36.0% |
| Q2 2020 | $3,074,000 | +33.6% | 203,806 | -18.2% | 0.02% | +19.0% |
| Q1 2020 | $2,301,000 | +3.6% | 249,006 | +9.2% | 0.02% | +40.0% |
| Q4 2019 | $2,221,000 | +24.4% | 228,106 | +2.5% | 0.02% | +36.4% |
| Q3 2019 | $1,785,000 | -32.1% | 222,606 | +5.7% | 0.01% | -38.9% |
| Q2 2019 | $2,627,000 | +157.8% | 210,506 | +181.0% | 0.02% | +157.1% |
| Q1 2019 | $1,019,000 | +43.5% | 74,905 | +1.1% | 0.01% | +16.7% |
| Q4 2018 | $710,000 | -14.5% | 74,105 | +8.0% | 0.01% | 0.0% |
| Q3 2018 | $830,000 | -17.3% | 68,632 | +6.7% | 0.01% | -14.3% |
| Q2 2018 | $1,004,000 | +1.1% | 64,332 | -2.6% | 0.01% | +16.7% |
| Q1 2018 | $993,000 | – | 66,032 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |